Chair:
Dr. Adolfo de la Fuente
MD Anderson Cancer Center Madrid, España
09:10 - 09:30High Risk AML characteristics and biology
Carolina Martinez Laperche
Hospital General Universitario Gregorio Marañón. Madrid, España
09:30 - 09:50Management of secondary AML, an aggressive approach
Dr. Jeffrey E. Lancet
Moffitt Cancer Center. Tampa, EEUU
09:50 - 10:10Intensive chemotherapy in myelodisplastic syndromes
Dr. Guillermo García-Manero
MD Anderson Cancer Center, Houston, EEUU
10:10 - 10:25Discussion
Chair:
Miguel Ángel Sanz
Hospital Universitario y Politécnico La Fe. Valencia, España
10:55 - 11:15Targeting epigenetic mechanisms
Dr. Alba Maiques-Díaz
IDIBAPS. Barcelona, España
11:15 - 11:35Hereditary myeloid neoplasms
Dr. José Cervera
Hospital Universitario y Politécnico La Fe. Valencia, España
11:35 - 11:50Discussion
Chairs:
Dr. Adolfo de la Fuente
MD Anderson Cancer Center Madrid, España
Dr. Elias Jabbour
MD Anderson Cancer Center, Houston, EEUU
11:50 - 12:10Master pathways in B-ALL: PETHEMA
Dr. Josep-María Ribera
ICO-Hospital Universitari Germans Trias i Pujol. Josep Carreras Research Institute. Badalona, España
12:10 - 12:30Tailored induction therapy in ALL
Dr. Elias Jabbour
MD Anderson Cancer Center, Houston, EEUU
12:30 - 12:50CAR-T in ALL
Dr. Claudia Rossig
Universit of Münster NRW, Germany
12:50 - 13:05Discussion
Chairs:
Dr. Guillermo Garcia-Manero,
Anderson Cancer Center, Houston, EEUU
Dr. Adolfo de la Fuente
MD Anderson Cancer Center Madrid, España
13:05 - 13:25Improving outcomes in low risk MDS
Dr. Pierre Fenaux
Hôpital Avicenne. Paris, France
13:25 - 13:45Managing myelophibrosis after Ruxolitinib failure
Dr. Valentín García Gutiérrez
Hospital Universitario Ramón y Cajal. Madrid, España
13:45 - 14:00Discussion
Chair:
Dr. Adolfo de la Fuente
MD Anderson Cancer Center Madrid, España
16:00 - 16:20Risk stratification for myeloid malignancies
Dr. Miguel Ángel Sanz
Hospital Universitario y Politécnico La Fe. Valencia, España
16:20 - 16:40Immumotherapy in AML
Dr. Naval Daver
MD Anderson Cancer Center, Houston, EEUU
16:40 - 17:00Targeting IDH
Dr. Adolfo de la Fuente
MD Anderson Cancer Center Madrid, España
17:00 - 17:20Targeting bone marrow inflammation with regulatory T cells
Dr. Simrit Parmar
MD Anderson Cancer Center, Houston, EEUU
17:20 - 17:40The role of maintenance with FLT3 inhibitors
Dr. Jorge Sierra
Hospital de la Santa Creu i Sant Pau. Barcelona, España
17:40 - 17:55Discussion
Chairs:
Dr. Miguel Ángel Sanz
Hospital Universitario y Politécnico La Fe. Valencia, España
Dr. Guillermo García-Manero
MD Anderson Cancer Center, Houston, EEUU
17:55 - 18:15Molecular point of view and dysregulation
Dr. Joaquín Sánchez
Hospital Universitario Reina Sofía. Córdoba, España
18:15 - 18:35Targeting Bcl2 and MCL1
Dr. Elias Jabbour
MD Anderson Cancer Center, Houston, EEUU
18:35 - 18:55Targeting apoptosis in Melodisplastic sindromes
Dr. Guillermo Garcia-Manero
MD Anderson Cancer Center, Houston, EEUU
18:55 - 19:10Discussion